PanTher Therapeutics Advances PTM-101 with Phase 1b Dose Escalation Completion in Pancreatic Cancer and Appoints Oncology Veteran Tim Clackson to Board
PanTher Therapeutics, a clinical-stage biotechnology company developing implant-based localized cancer therapies, has announced a key clinical and corporate milestone in its lead program PTM-101 for pancreatic ductal adenocarcinoma (PDAC). The company confirmed that it has successfully completed the dose escalation portion of its Phase 1b clinical trial evaluating PTM-101 and has identified a 400 mg paclitaxel-containing implant as the recommended Phase 2 dose (RP2D) when used alongside neoadjuvant standard-of-care chemotherapy.
In addition to the clinical update, PanTher also announced the appointment of experienced oncology industry leader Dr. Tim Clackson to its Board of Directors, strengthening its leadership team as it advances its innovative localized drug delivery platform toward later-stage development.
Together, these announcements mark an important step forward for PanTher as it seeks to transform treatment paradigms in one of the most aggressive and difficult-to-treat solid tumors.
Advancing a Localized Approach to Pancreatic Cancer Treatment
Pancreatic ductal adenocarcinoma remains one of the most lethal forms of cancer, largely due to its late diagnosis, rapid disease progression, and limited treatment options. Even in cases where patients are diagnosed at a non-metastatic stage, outcomes remain poor, and many patients are unable to tolerate the intensity of systemic chemotherapy regimens required to control disease progression.
PanTher Therapeutics is seeking to address these challenges through a novel localized drug delivery platform designed to administer chemotherapy directly at the tumor site. Its lead candidate, PTM-101, is an implantable formulation of paclitaxel designed to be placed directly onto the tumor surface during diagnostic or staging procedures.
By delivering high concentrations of chemotherapy locally rather than systemically, the company aims to maximize anti-tumor activity while minimizing systemic toxicity—a major limitation of traditional treatment approaches.
Phase 1b Dose Escalation Results Support RP2D Selection
The company’s latest update is based on its ongoing Phase 1b clinical trial of PTM-101 in patients with newly diagnosed, treatment-naïve, non-metastatic pancreatic cancer. The study is designed as an open-label, multicenter, single-arm trial evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of PTM-101 when combined with standard neoadjuvant chemotherapy.
During the dose escalation phase, patients were treated with increasing doses of PTM-101, including 200 mg and 400 mg paclitaxel implant levels, alongside standard-of-care FOLFIRINOX chemotherapy.
Across a total of 12 patients evaluated in this phase, the results demonstrated a strong safety and pharmacokinetic profile. Importantly, no systemic exposure to paclitaxel was detected at any of the evaluated dose levels, with plasma concentrations remaining below quantifiable limits. This finding suggests that the drug remains localized at the tumor site, consistent with the intended design of the implant technology.
In addition, no significant implant-related toxicities were observed, and there was no evidence of additive toxicity when PTM-101 was used in combination with standard chemotherapy. These findings are particularly important in pancreatic cancer, where treatment-related toxicity often limits the ability to deliver full-dose chemotherapy.
Based on these results, the study’s Safety Committee has endorsed the 400 mg dose as the recommended Phase 2 dose. Notably, this dose represents a level equivalent to four times the maximum tolerated systemic dose of paclitaxel, highlighting the advantage of localized delivery in achieving higher drug exposure at the tumor site without increasing systemic toxicity.
Promising Early Clinical Activity in First-in-Human Study
The Phase 1b results build on encouraging findings from PanTher’s earlier first-in-human clinical study of PTM-101. In that initial trial, the therapy demonstrated a favorable safety profile at a 100 mg dose and showed early signs of anti-tumor activity, including tumor volume reductions of up to 70% in treated patients.
These early observations provided the foundation for continued dose escalation and further clinical evaluation in combination with standard-of-care chemotherapy.
Together, the clinical data suggest that PTM-101 may offer a new therapeutic approach for patients with localized pancreatic cancer, where early and aggressive intervention can be critical in determining long-term outcomes.
Targeting a Critical Window in Non-Metastatic Disease
Approximately half of all patients diagnosed with pancreatic ductal adenocarcinoma present with non-metastatic disease at the time of diagnosis. For these patients, there remains a potential window for curative-intent treatment through a combination of chemotherapy and surgical resection.
However, even in this early stage, treatment is challenging. Standard-of-care regimens such as FOLFIRINOX, while effective, are associated with significant systemic toxicity that can limit dose intensity and patient tolerability.
PTM-101 is designed to address this gap by providing sustained, high-dose local chemotherapy directly to the tumor site immediately after diagnosis. The implant is administered during a routine staging laparoscopy and is designed to deliver approximately six weeks of continuous drug exposure.
By adding a fourth chemotherapy agent directly at the tumor site, PTM-101 is intended to enhance tumor kill while maintaining compatibility with systemic neoadjuvant regimens. This approach aims to deepen treatment responses before the disease has an opportunity to spread or become metastatic.
Expansion Phase Now Underway
Following completion of the dose escalation phase, PanTher has initiated the dose expansion portion of the Phase 1b study (ClinicalTrials.gov Identifier: NCT06673017). This next stage will enroll approximately 15 additional patients across multiple clinical sites in the United States.
The expansion cohort will further evaluate the safety, tolerability, and preliminary efficacy of PTM-101 at the selected 400 mg dose in combination with FOLFIRINOX chemotherapy in patients with borderline resectable or locally advanced pancreatic cancer.
The study will also continue to assess pharmacokinetic behavior, local tumor response, and surgical outcomes in patients receiving the combination regimen.
PanTher expects to report topline data from the Phase 1b study in the first half of 2027, marking a key upcoming milestone for the program.
Strategic Board Appointment Strengthens Leadership
Alongside its clinical progress, PanTher Therapeutics has strengthened its corporate leadership with the appointment of Dr. Tim Clackson to its Board of Directors.
Dr. Clackson brings more than 30 years of experience in oncology drug development and biotechnology company leadership. Throughout his career, he has played a key role in advancing multiple oncology-focused companies and supporting the development of novel cancer therapies from early discovery through clinical and commercial stages.
His appointment reflects PanTher’s intention to build a seasoned leadership team capable of guiding the company through late-stage clinical development and eventual commercialization.
Leadership Commentary Highlights Clinical and Strategic Momentum
Laura Indolfi, Ph.D., Chief Executive Officer and Co-founder of PanTher Therapeutics, emphasized the importance of integrating PTM-101 into the treatment pathway at the earliest stages of disease.
She noted that in localized pancreatic cancer, treatment decisions made at diagnosis can significantly influence long-term outcomes. By integrating PTM-101 directly into neoadjuvant treatment regimens, the company aims to enhance anti-tumor activity without increasing systemic side effects.
Dr. Indolfi also highlighted the broader goal of achieving deeper and more durable responses prior to surgical intervention, potentially reducing the risk of metastatic progression.
Dr. Tim Clackson echoed this optimism, describing PTM-101 as a highly differentiated approach to one of oncology’s most challenging disease areas. He emphasized that the therapy’s localized delivery system allows for high-dose, sustained exposure directly at the tumor site while integrating seamlessly into existing clinical workflows.
According to Clackson, this combination of simplicity, compatibility with standard care, and potential clinical benefit could support broad adoption if later-stage studies confirm the early results.
Expanding Pipeline Beyond Pancreatic Cancer
PTM-101 represents the lead candidate in PanTher Therapeutics’ broader pipeline of implantable drug delivery systems designed to treat solid tumors. In addition to pancreatic cancer, the company is developing polymer-based formulations aimed at addressing other difficult-to-treat cancers where localized therapy could improve outcomes.
This platform-based approach positions PanTher to potentially expand its technology across multiple oncology indications, leveraging the same core delivery mechanism to target different tumor types.
With the completion of dose escalation, identification of the recommended Phase 2 dose, and the initiation of expansion cohorts, PTM-101 is now moving into a more advanced stage of clinical development.
As pancreatic cancer continues to present significant treatment challenges, PanTher’s localized drug delivery approach represents a novel attempt to improve outcomes by intensifying therapy directly at the tumor site while avoiding the systemic toxicities associated with high-dose chemotherapy.
With topline Phase 1b results expected in 2027, PTM-101 will remain a closely watched program in the evolving landscape of pancreatic cancer treatment innovation.
bout PTM-101
PanTher’s most advanced investigational product candidate, PTM-101, is an absorbable thin film formulation of paclitaxel for non-metastatic pancreatic cancer. PTM-101 is designed to deliver continuous, long-lasting, high-dose chemotherapy to the tumor with little to no systemic exposure. The product, laparoscopically implanted at the tumor site, easily integrates with common minimally invasive procedures used in staging pancreatic cancer. PTM-101 is currently being evaluated in a Phase 1b clinical trial (NCT06673017) with support from the Cancer Prevention & Research Institute of Texas (CPRIT) DP220066.
About PanTher Therapeutics
PanTher Therapeutics is a clinical-stage oncology company leveraging combined expertise in drug formulation and materials science to develop and commercialize potent, localized implantable medicines that can improve outcomes for patients with solid tumors. PanTher’s Sagittari™ platform enables the formulation of anti-cancer medicines in a wide range of flexible, polymer-based dosage forms that can be administered to the surface of a cancerous organ or implanted directly into a tumor.
The drug product is tunable and engineered to continuously deliver the drug for weeks or months at a desired dose level directly to the tumor site, avoiding the dose-limiting side effects of off-target toxicity with systemic therapies, while peserving delivery of high doses locally. The company has offices in Austin, Texas, and Watertown, Massachusetts.
